39results about How to "Eliminate side effects" patented technology

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention particularly relates to a glycosylated dendrimer for co-delivery of small interfering RNA (Ribonucleic Acid) and small molecular drugs as well as a preparation method and application of the glycosylated dendrimer. The nano platform provided by the invention is characterized in that an anti-inflammatory drug resveratrol (Res) and electrostatic adsorption small interfering RNA (si-Cp2e1) are loaded in a glycosylated dendrimer G5-Gal. The preparation method and the application comprise the following steps: preparation of G5-Gal, preparation of Res (at) G5-Gal, and preparation of Res (at) G5-Gal / si-Cp2e1. The preparation method is simple, the required raw materials are easy to obtain, the synthesis process is simple and convenient, separation and purification are easy, and the synthesized nano-drug has a liver targeting capability, can realize dual treatment of small molecule drug-small interfering RNA, and has a potential application prospect in the aspect of treatment of alcohol-related liver diseases.

The present invention relates to glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) p-20637

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.

The present application relates to the technical field of external use patch, disclose a kind of neck shoulder waist leg pain health care patch and its preparation method, the health care patch includes backing layer, ointment layer and anti-adhesion release layer;Ointment layer raw material includes: traditional Chinese medicine extract flow leaching paste, L- (+) -tartaric acid, PVP K30, PEG-400, ternary eutectic solvent, polyacrylate pressure sensitive adhesive matrix and ultrafine medicinal powder.Preparation, after flow leaching paste, tartaric acid etc. are mixed, gel precursor is formed by vacuum dewatering and dealcoholization, swelling is added again with eutectic solvent, and then mixed with pressure sensitive adhesive matrix and medicinal powder high shear, finally coating solidification.The present application constructs physical crosslinking gel network in colloid interior and promotes effective component acid-base salt formation, effectively avoids polar component crystallization precipitation, reduces the skin irritation caused by drug burst release, simultaneously improves the cohesion of ointment, realizes long-acting smooth drug release.

A GPC3-targeting antibody-interferon α fusion protein and a use thereof are disclosed in this invention. The fusion protein consists of an A chain and a B chain; wherein the amino acid sequence of the A chain is as shown in SEQ ID NO: 1, and the amino acid sequence of the B chain is as shown in SEQ ID NO: 2. The killing effect on target cells, especially tumor cells, can be significantly improved, and toxic side effects caused by binding to non-target cells are significantly reduced. The fusion protein has better safety, lower production cost, and good freeze-thaw stability.

Provided are a compound used as a BCR-ABL inhibitor, namely a compound of formula (I), or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the compound. Moreover, the present invention relates to a use of the compound in the preparation of a drug for treating BCR-ABL related diseases.

A pharmaceutical composition for the treatment of cancer and a use thereof, belonging to the field of medicine. The pharmaceutical composition consists of an FAK inhibitor and a CD44 inhibitor. Also provided is a drug combination of an FAK inhibitor and a CD44 inhibitor for the treatment of cancer. The CD44 inhibitor and FAK inhibitor drug combination can have synergistic effects, significantly improving tumor inhibition effects, reducing toxic side effects, and overcoming tumor drug resistance, thereby providing a good choice for clinical treatment of cancer.

The invention relates to the technical field of biological medicine, in particular to selenium and application of a selenium composition, a nasal composition and application of the nasal composition. The invention provides application of selenium in inhibition of nasal cavity or airway epithelium inflammatory factor expression and a nasal composition containing the selenium. The selenium element is used for regulating and controlling a signal channel, so that the expression of key inflammatory factors in epithelial cells of the nasal cavity or the airway is effectively reduced, the level of reactive oxygen species (ROS) of the epithelial cells of the nasal cavity or the airway is reduced, and the dual effects of inflammation resistance and oxidation resistance are achieved. Therefore, the nasal composition containing the selenium element can effectively block the preinflammatory syndrome driven by upstream oxidative stress by regulating and controlling dual mechanisms of inflammation and oxidative stress reaction, and nasal cavity or airway diseases such as rhinitis and allergic rhinitis are relieved and treated from the source.

The application provides a camellia plant endophytic bacteria, a bacterial agent thereof and an anti-influenza virus A application; the camellia plant endophytic bacteria is Bacillus thuringiensis, which is preserved in the China General Microbiological Culture Collection Center with a preservation number of CGMCC No.32945. The fermentation product of the strain shows good antiviral activity in in vitro and in vivo experiments, can effectively inhibit the replication of influenza virus, and protect infected mice from lethal influenza virus; also shows the effect of regulating immune response, enhances the secretion of IFN-gamma by down-regulating the secretion of pro-inflammatory factors such as IL-6 and IL-10, thereby improving the immune resistance of the body.

The application discloses a kind of multi-band electromagnetic wave auxiliary methods for assisting in treating hypertension, and specifically includes the following steps: S1, healthy human biological information acquisition;S2, resonance reflection wave collection and storage;S3, treatment information extraction and processing;S4, treatment instrument debugging and parameter setting;S5, patient pretreatment and positioning;S6, personalized treatment implementation;S7, treatment process monitoring;S8, course evaluation and scheme optimization;The application relates to the technical field of electromagnetic wave therapy. The multi-band electromagnetic wave auxiliary method for assisting in treating hypertension, by using multi-band treatment wave cooperation treatment, breaks through the limitation of single waveband curative effect, and different frequency bands of treatment wave are respectively used for nerve regulation, vasodilation, endothelial function improvement and other multiple blood pressure regulation pathways, to realize systematic combined intervention, significantly improve the comprehensiveness and stability of treatment.

This invention discloses an antibiotic patch and its application. The antibiotic patch includes a transdermal microneedle module, an antibiotic reservoir layer, and an osmotic pressure driving module, with the reservoir layer and the driving module separated by an elastic membrane. The osmotic pressure driving module includes a water chamber, a propulsion layer, and an osmotic pressure active sheet. It generates a constant thrust through unidirectional permeation of the semi-permeable membrane, propelling the antibiotic through the hollow microneedles for transdermal infusion and achieving zero-level release. The independent antibiotic reservoir layer can hold large doses of antibiotics, and it is also equipped with a filling port and a venting port to ensure flexible and stable medication administration. The antibiotic patch is suitable for various scenarios, including home and outdoor use, and can reduce the risk of antibiotic resistance and side effects, providing a convenient and efficient new solution for the treatment of bacterial infections.

The present invention relates to an interleukin-2 (IL-2) mutant and an application thereof. Key sites were selected by means of computer-aided molecular design, and an IL-2 mutant phage display library was constructed based on synthetic biology techniques and combined with forward and reverse screening strategies to screen for a biased IL-2 mutant. Compared with wild-type IL-2, the IL-2 mutant of the present invention has reduced IL-2Rα receptor affinity and increased or equivalent IL-2Rβ receptor affinity, and can activate effector T cells, activate NK cells, and stimulate the release of interferon γ in a biased manner. Also provided in the present invention are a nucleic acid encoding the novel IL-2 mutant and a vector and a host cell comprising the nucleic acid, and further provided are a method for preparing the novel IL-2 mutant, a pharmaceutical combination comprising the novel IL-2 mutant, and a therapeutic use of the novel IL-2 mutant.

Disclosed is a prophylactic or therapeutic drug for Parkinson's disease, which comprises a trisulfide compound and is characterized by being administered in combination with a drug that is used for a dopamine supplementation therapy.

A pyridine derivative and use thereof. The compound has an obvious inhibitory effect on the activity of KRAS and PI3K proteins, can be used as a KRAS and / or PI3K protein inhibitor, and can be used for preparing a drug for treatment of diseases such as KRAS or PI3K protein-mediated cancer. The compound has an extremely strong inhibitory effect on a KRAS G12C inhibitor (e.g. AMG-510) drug-resistant cancer cells , and has a wide application prospect thereof.

This invention discloses the application of an anionic open-ring cucurbituril derivative in improving the water solubility and antitumor activity of paclitaxel. The inclusion complex is formed by the assembly of anionic open-ring cucurbituril as the host molecule and paclitaxel as the guest molecule through non-covalent host-guest interactions, wherein the molar ratio of paclitaxel to anionic open-ring cucurbituril is 1-10:1. By forming a stable host-guest inclusion complex, the extremely poor water solubility and chiral stability of paclitaxel are significantly improved, effectively enhancing its antitumor efficacy and showing broad application prospects in targeted drug delivery and clinical oncology treatment.

Provided are a pyrimidine-fused cyclic compound represented by formula (A) having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, a pharmaceutical composition containing the compound, and an application thereof in the preparation of anticancer drugs

This invention discloses a tumor electric field therapy device and system. The tumor electric field therapy device consists of a frame and electrode modules. The frame forms the skeleton structure of the therapy device, and the electrode modules are attached to the frame. Each electrode module has several electrode contacts, and each electrode contact can be either an active or passive contact. The active contacts can form a circuit with a radio frequency generation module. When the therapy device is implanted into the tumor resection site, all electrode contacts become active contacts, and each electrode contact forms a circuit with the radio frequency generation module, distinguishing between normal tissue and diseased tissue. After distinguishing between normal tissue and diseased tissue, the electrode contacts in the normal tissue area become passive contacts, and the electrode contacts in the diseased tissue area become active contacts, enabling targeted treatment of the diseased tissue and thus reducing the side effects of electric field therapy.

Provided are a 5-benzylimidazole compound represented by formula I and a preparation method therefor and a use thereof. The compound of formula I and a pharmaceutically acceptable salt thereof can be decomposed in plasma to release the 5-benzylimidazole compound having a pharmacological effect, thereby exerting anesthetic and / or sedative-hypnotic effects in vivo. The compound of formula I has the characteristics of rapid onset, high potency, good circulation stability, and good safety, rapid injection does not cause severe blood pressure fluctuations, good anesthetic and / or sedative-hypnotic effects can also be achieved by oral administration, and the present invention has wide application prospects.

Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or deuterate thereof. The compound of formula I can be used as a kinase inhibitor, as a drug for the treatment of ROS1, NTRK, ALK and other kinase-mediated diseases.

The present invention is to provide a pharmaceutical composition for suppressing invasion of cancer, which comprises siRNA that suppresses expression of CHST15 gene, and a method for suppressing invasion of cancer.

The invention discloses an mRNA (messenger ribonucleic acid) delivery system based on a nucleic acid nanostructure as well as a preparation method and application of the mRNA delivery system. The mRNA delivery system comprises an mRNA scaffold chain, an RNA staple chain, a lipid-nucleic acid coupling chain and an auxiliary lipid; the mRNA scaffold chain comprises a nucleic acid sequence for coding target protein mRNA; the mRNA scaffold chain and the RNA staple chain are self-assembled through complementary base pairing to form a nucleic acid nanostructure; the lipid-nucleic acid coupling chain comprises a lipid molecule and a nucleic acid chain coupled with the lipid molecule. According to the invention, mRNA molecules of coding functional protein are used as scaffold chains to be accurately integrated into the nucleic acid nanostructure, so that the purpose of protecting and delivering mRNA is achieved, and the effect of accurately regulating and controlling the expression of target protein is achieved.

The present invention relates to a bispecific antibody against CTLA4 and PD-1, wherein the antibody is used for treating tumors, is administered in combination with an anti-VEGFR2 monoclonal antibody or an anti-VEGF monoclonal antibody, and comprises a first protein functional region targeting PD-1 and a second protein functional region targeting CTLA4, the first protein functional region being an immunoglobulin and the second protein functional region being a single-chain antibody, or the first protein functional region being a single-chain antibody and the second protein functional region being an immunoglobulin.

Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or deuterate thereof. The compound of formula I can be used as a kinase inhibitor, as a drug for the treatment of ROS1, NTRK, ALK and other kinase-mediated diseases.

The application discloses poplar phellinus polysaccharide SVP-50-1 and a preparation method and application thereof, and belongs to the field of biological medicines.The poplar phellinus polysaccharide SVP-50-1 is obtained by water extraction and 50% ethanol solution precipitation of poplar phellinus fruiting bodies.The poplar phellinus polysaccharide SVP-50-1 can regulate a tumor metabolic process, inhibit the activity of a tumor cell mitochondrial respiratory chain and an oxidative phosphorylation process, thereby inhibiting the energy source of tumor cells, and achieving an anti-tumor effect.The poplar phellinus polysaccharide SVP-50-1 can play a synergistic effect when combined with radiotherapy and chemotherapy drugs.The combined treatment strategy can significantly improve the curative effect of an existing tumor treatment, while reducing adverse reactions, and provides a new optimized scheme for clinical tumor treatment.

This invention belongs to the field of biomedical technology, specifically relating to the application of α-ketoglutarate in the preparation of drugs that enhance the sensitivity of aquatic pathogens to florfenicol. This invention is the first to discover that α-ketoglutarate can significantly enhance the bactericidal effect of florfenicol against aquatic pathogens. Combined injection of α-ketoglutarate and florfenicol can reduce the number of bacteria in the liver and spleen of aquatic organisms, including fish, infected with aquatic pathogens, thus reducing damage to the organs and tissues of fish and other aquatic organisms and improving their survival rate. Therefore, α-ketoglutarate can be used as a synergist for florfenicol. Its combined application in the preparation of compound antibacterial agents can improve the efficacy of aquatic antibacterial drugs, significantly reduce the dosage of antibacterial drugs, and consequently reduce side effects and drug residues. This has significant application value and importance in the production and development of drugs against aquatic pathogens.